These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2783668)

  • 21. [Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
    Ponz E; Campistol JM; Ribalta T; Montoliú J; Ramírez J; Almirall J; Revert L
    Rev Clin Esp; 1991 Feb; 188(2):85-7. PubMed ID: 2041907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
    Nakamura M; Weil WB; Kaufman DB
    Pediatr Nephrol; 1989 Jan; 3(1):80-2. PubMed ID: 2702092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model.
    Gehlbach PL; Purple RL; Hallaway PE; Hedlund BE
    Invest Ophthalmol Vis Sci; 1993 Sep; 34(10):2871-7. PubMed ID: 7689545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 25. Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
    Nephrol Dial Transplant; 1993; 8 Suppl 1():1-4. PubMed ID: 8389013
    [No Abstract]   [Full Text] [Related]  

  • 26. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea.
    Lee EJ; Kim SJ; Choung HK; Kim JH; Yu YS
    J Neuroophthalmol; 2008 Dec; 28(4):269-77. PubMed ID: 19145123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
    Mathys B; Baeck A; Verougstraete C; Verstappen A; D'Haene M; Zanen A
    Bull Soc Belge Ophtalmol; 1988; 229():49-60. PubMed ID: 3273254
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deferoxamine (Desferal)-induced ocular toxicity.
    Kaplinsky C; Stark B; Goshen Y; Yaniv I; Bashara S; Zaizov R
    Pediatr Hematol Oncol; 1988; 5(4):293-7. PubMed ID: 3152975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing serum aluminum in CAPD patients.
    Montenegro J; Aguirre R; Saracho R; Moina I; Martínez I
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT; Kurtz SB; Mussman GV
    Am J Med; 1987 Feb; 82(2):367-70. PubMed ID: 3812538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Visual impairment due to optic neuropathy in 2 patients on amiodarone therapy, i.e. ethambutol and isoniazide].
    Polak BC; Tutein Nolthenius PA; Rietveld E
    Ned Tijdschr Geneeskd; 2001 May; 145(19):922-6. PubMed ID: 11387869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.